The latest price target for Actinium Pharma (AMEX:ATNM) was reported by HC Wainwright & Co. on April 1, 2025. The analyst firm set a price target for $4.00 expecting ATNM to rise to within 12 months (a possible 234.73% upside). 17 analyst firms have reported ratings in the last year.

The latest analyst rating for Actinium Pharma (AMEX:ATNM) was provided by HC Wainwright & Co., and Actinium Pharma reiterated their buy rating.

There is no last upgrade for Actinium Pharma

The last downgrade for Actinium Pharmaceuticals Inc happened on February 21, 2023 when William Blair changed their price target from N/A to N/A for Actinium Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Actinium Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Actinium Pharma was filed on April 1, 2025 so you should expect the next rating to be made available sometime around April 1, 2026.

While ratings are subjective and will change, the latest Actinium Pharma (ATNM) rating was a reiterated with a price target of $4.00 to $4.00. The current price Actinium Pharma (ATNM) is trading at is $1.20, which is out of the analyst’s predicted range.